Indian Immunologicals' chikungunya, JE vaccines set for human studies
This article was originally published in Scrip
Indian Immunologicals (IIL) is developing a live attenuated chikungunya vaccine in collaboration with an institute in the US. The firm, which hopes to see a fast track regulatory approach in India for some if its products, is also upbeat about the prospects of its vaccines for Japanese encephalitis (JE) and cervical cancer.
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.